Bin-Kuan Chou
Overview
Explore the profile of Bin-Kuan Chou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
1590
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Choi I, Lim H, Cho H, Oh Y, Chou B, Bai H, et al.
Elife
. 2020 Feb;
9.
PMID: 32011235
Generation of skeletal muscle cells with human pluripotent stem cells (hPSCs) opens new avenues for deciphering essential, but poorly understood aspects of transcriptional regulation in human myogenic specification. In this...
2.
Hoggatt J, Singh P, Tate T, Chou B, Datari S, Fukuda S, et al.
Cell
. 2017 Dec;
172(1-2):191-204.e10.
PMID: 29224778
Hematopoietic stem cell transplantation is a potential curative therapy for malignant and nonmalignant diseases. Improving the efficiency of stem cell collection and the quality of the cells acquired can broaden...
3.
Chou B, Gu H, Gao Y, Dowey S, Wang Y, Shi J, et al.
Stem Cells Transl Med
. 2015 Mar;
4(4):320-32.
PMID: 25742692
Reprogramming human adult blood mononuclear cells (MNCs) cells by transient plasmid expression is becoming increasingly popular as an attractive method for generating induced pluripotent stem (iPS) cells without the genomic...
4.
All A, Gharibani P, Gupta S, Bazley F, Pashai N, Chou B, et al.
PLoS One
. 2015 Jan;
10(1):e0116933.
PMID: 25635918
Induced pluripotent stem (iPS) cells are at the forefront of research in regenerative medicine and are envisaged as a source for personalized tissue repair and cell replacement therapy. Here, we...
5.
Chou B, Cheng L
Cell Stem Cell
. 2013 Sep;
13(3):261-2.
PMID: 24012365
While most factors used as reprogramming transgenes can be replaced by other means, Oct4 has remained essential until now. Three recent papers have now broken this barrier through the use...
6.
Wang Y, Chou B, Dowey S, He C, Gerecht S, Cheng L
Stem Cell Res
. 2013 Aug;
11(3):1103-16.
PMID: 23973800
Large-scale production of human induced pluripotent stem cells (hiPSCs) by robust and economic methods has been one of the major challenges for translational realization of hiPSC technology. Here we demonstrate...
7.
8.
Yu Y, Liang D, Tian Q, Chen X, Jiang B, Chou B, et al.
Stem Cells
. 2013 Jun;
32(2):349-63.
PMID: 23765875
Reprogramming of somatic cells to induced pluripotent stem cells (iPSCs) shares much similarity to the cancer initiation process, and the molecular mechanisms underlying both processes remain to be elucidated. Here,...
9.
Dowey S, Huang X, Chou B, Ye Z, Cheng L
Nat Protoc
. 2012 Oct;
7(11):2013-21.
PMID: 23080273
Several human postnatal somatic cell types have been successfully reprogrammed to induced pluripotent stem cells (iPSCs). Blood mononuclear cells (MNCs) offer several advantages compared with other cell types. They are...
10.
Ye Z, Chou B, Cheng L
Int J Hematol
. 2012 May;
95(6):601-9.
PMID: 22619021
Postnatal hematopoietic stem cells (HSCs) from umbilical cord blood and adult marrow/blood have been successfully used for treating various human diseases in the past several decades. However, the availability of...